New drugs have made America’s deadliest cancer more treatable than ever. So why aren’t they reaching patients?

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in ...

Patients — and their doctors — have been desperate for a more effective pancreatic cancer treatment for decades. Now one ...

Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...

A major analysis of over 250,000 older adults with metastatic non-small cell lung cancer found that fewer than half received systemic treatment, despite advances in targeted and immunotherapies. The ...

People with advanced lung cancer represent a distinct group whose needs remain understudied, especially compared with people diagnosed with limited-stage disease. Fortunately, novel treatments such as ...

A significant discordance exists between patient preferences and received care in advanced cancer, with 37% receiving life-extending treatment despite preferring comfort-focused care. No survival ...

Oral agent in second-line more than doubled median PFS in patients with ESR1 muta ...

Advanced cardiovascular-kidney-metabolic syndrome was associated with increased risk for incident cancer among a large cohort ...